---
input_text: Gastric cancer with Fanconi anemia in adolescent and young adult patient
  diagnosed by comprehensive genome profiling using next-generation sequencing. Recently,
  the results of gastric cancer treatment have improved; however, its characteristics
  in adolescents and young adults are not well known. We report the case of a patient
  with advanced gastric cancer, Fanconi anemia (FA), and primary biliary cholangitis.
  A 26-year-old woman visited a local physician complaining of epigastralgia. Esophagogastroduodenoscopy
  revealed edematous changes with poor distension and circumferential thickened folds
  with erosions in the gastric body. Biopsy results of the lesion specimens revealed
  poorly differentiated adenocarcinoma. Abdominal contrast-enhanced computed tomography
  revealed gastric wall with irregular thickness, several nodules in the peritoneal
  cavity, and a mass lesion in the right ovary. We diagnosed the patient with T4N2M1
  stage IV gastric cancer accompanied by peritoneal and ovarian metastases and initiated
  nivolumab with S-1 plus oxaliplatin as the first-line treatment regimen. Because
  of immune-related adverse events after one course of systemic treatment, the regimen
  was changed to ramucirumab combined with nab-paclitaxel chemotherapy as the second-line
  treatment. After three cycles of weekly nab-paclitaxel with ramucirumab, the decreased
  platelet count did not recover, and her general condition gradually deteriorated.
  Comprehensive genome profiling using next-generation sequencing was performed to
  determine the feasibility of genotype-matched therapies. Alterations in FA complementation
  group A (FANCA) F1263del (49.1%) and E484Q (12.3%), which encode a key component
  of the multiprotein FA complex, were identified. The patient died 10 months after
  treatment initiation. In conclusion, when treating malignancies in adolescent and
  young adult patients, the genomic background should be considered.
raw_completion_output: |-
  primary_disease: Gastric cancer

  medical_actions: Comprehensive genome profiling using next-generation sequencing; Esophagogastroduodenoscopy; Biopsy; Abdominal contrast-enhanced computed tomography; Initiated nivolumab with S-1 plus oxaliplatin; Changed to ramucirumab combined with nab-paclitaxel chemotherapy

  symptoms: Epigastralgia; Edematous changes with poor distension; Circumferential thickened folds with erosions; Gastric wall with irregular thickness; Several nodules in the peritoneal cavity; A mass lesion in the right ovary; Decreased platelet count

  chemicals: Nivolumab; S-1; Oxaliplatin; Ramucirumab; Nab-paclitaxel

  action_annotation_relationships: Esophagogastroduodenoscopy TREATS epigastralgia IN Gastric cancer; Biopsy TREATS edematous changes with poor distension IN Gastric cancer; Abdominal contrast-enhanced computed tomography TREATS circumferential thickened folds with erosions IN Gastric cancer; Initiated nivolumab with S-1 plus oxaliplatin TREATS Gastric wall with irregular thickness IN Gastric cancer; Changed to ramucirumab combined with nab-paclitaxel chemotherapy TREATS decreased platelet count IN Gastric cancer; Comprehensive genome profiling using next-generation sequencing TREATS Gastric cancer
prompt: |+
  From the text below, extract the following entities in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  Comprehensive genome profiling using next-generation sequencing TREATS Gastric cancer

  ===

extracted_object:
  primary_disease: MONDO:0001056
  medical_actions:
    - Comprehensive genome profiling using next-generation sequencing
    - MAXO:0001193
    - Biopsy
    - Abdominal contrast-enhanced computed tomography
    - Initiated nivolumab with S-1 plus oxaliplatin
    - Changed to ramucirumab combined with nab-paclitaxel chemotherapy
  symptoms:
    - Epigastralgia
    - Edematous changes with poor distension
    - Circumferential thickened folds with erosions
    - Gastric wall with irregular thickness
    - Several nodules in the peritoneal cavity
    - A mass lesion in the right ovary
    - Decreased platelet count
  chemicals:
    - CHEBI:231614
    - S-1
    - CHEBI:31941
    - Ramucirumab
    - Nab-paclitaxel
  action_annotation_relationships:
    - subject: MAXO:0001193
      predicate: TREATS
      object: epigastralgia
      qualifier: MONDO:0001056
    - subject: <Biopsy>
      predicate: <TREATS>
      object: <edematous changes with poor distension>
      qualifier: <Gastric cancer>
      subject_qualifier: <None>
      object_qualifier: <None>
      subject_extension: <None>
      object_extension: <None>
    - subject: <Abdominal contrast-enhanced computed tomography>
      predicate: <TREATS>
      object: <circumferential thickened folds with erosions>
      qualifier: <Gastric cancer>
      subject_extension: <contrast-enhanced computed tomography>
    - subject: Initiated nivolumab with S-1 plus oxaliplatin
      predicate: TREATS
      object: Gastric wall with irregular thickness
      qualifier: MONDO:0001056
      subject_extension: nivolumab with S-1 plus oxaliplatin
    - subject: MAXO:0000647
      predicate: TREATS
      object: decreased platelet count
      qualifier: MONDO:0001056
      subject_extension: ramucirumab combined with nab-paclitaxel
    - subject: Comprehensive genome profiling
      predicate: TREATS
      object: HP:0012126
      subject_qualifier: using
      subject_extension: next-generation sequencing
named_entities:
  - id: MONDO:0019391
    label: Fanconi anemia
  - id: MAXO:0000747
    label: Hematopoietic stem cell transplantation (HSCT)
  - id: CHEBI:18198
    label: ADCs
  - id: CHEBI:4027
    label: cyclophosphamide
  - id: MAXO:0000750
    label: conditioning regimens
  - id: CHEBI:37153
    label: Calcineurin inhibitor
  - id: CHEBI:38215
    label: Calcium channel blocker
  - id: CHEBI:4031
    label: Cyclosporine
  - id: CHEBI:8069
    label: Phenobarbital
  - id: CHEBI:2668
    label: Amlodipine
  - id: MAXO:0000149
    label: Hematopoietic cell transplantation (HCT)
  - id: MAXO:0000016
    label: Cellular therapy
  - id: HP:0001871
    label: Blood dyscrasias
  - id: MAXO:0000595
    label: Radiography
  - id: HP:0005528
    label: Bone marrow failure
  - id: HP:0034057
    label: Congenital defects
  - id: CHEBI:28901
    label: Busulfan
  - id: CHEBI:44185
    label: Methotrexate
  - id: MONDO:0005233
    label: Non-small cell lung cancer (NSCLC)
  - id: CHEBI:33364
    label: Platinum
  - id: MAXO:0000647
    label: chemotherapy
  - id: HP:0030358
    label: Non-small cell lung cancer
  - id: MAXO:0001479
    label: Allogeneic hematopoietic stem cell transplantation (allo-HSCT)
  - id: HP:0002863
    label: Myelodysplasia
  - id: HP:0001909
    label: Leukemia
  - id: MONDO:0016624
    label: Hereditary anemia
  - id: MAXO:0001001
    label: Gene therapy
  - id: MONDO:0005570
    label: Hematological disorders
  - id: HP:0002664
    label: cancer
  - id: MONDO:0015253
    label: Diamond Blackfan anemia
  - id: MAXO:0000600
    label: Kidney replacement therapy (KRT)
  - id: HP:0000093
    label: Proteinuria
  - id: HP:0003259
    label: Elevated serum creatinine (SCr > 100micromol/l)
  - id: MONDO:0001529
    label: Bone marrow failure (BMF)
  - id: HP:0002860
    label: oral squamous cell carcinoma (SCC)
  - id: MONDO:0100339
    label: Fanconi anemia (FA)
  - id: CHEBI:28680
    label: Ara-C
  - id: CHEBI:27899
    label: Cisplatin
  - id: HP:0011793
    label: Malignant tumors
  - id: HP:0000818
    label: Endocrinopathies
  - id: HP:0002745
    label: Oral leukoplakia
  - id: CHEBI:64357
    label: rituximab
  - id: CHEBI:61049
    label: Tacrolimus
  - id: HP:0002910
    label: elevated liver function tests
  - id: CHEBI:125354
    label: plerixafor
  - id: CHEBI:231614
    label: Nivolumab
  - id: CHEBI:25016
    label: PBS
  - id: MONDO:0009693
    label: Multiple Myeloma
  - id: CHEBI:28876
    label: Melphalan
  - id: CHEBI:229764
    label: Selinexor
  - id: CHEBI:229762
    label: Eltanexor
  - id: HP:0006775
    label: Multiple Myeloma
  - id: CHEBI:229763
    label: exportin 1 inhibitors
  - id: MONDO:0015909
    label: aplastic anemia
  - id: HP:0004808
    label: Acute myeloid leukaemia
  - id: MAXO:0000004
    label: Surgery
  - id: MAXO:0000014
    label: Radiotherapy
  - id: MONDO:0001881
    label: Septic shock
  - id: MAXO:0001021
    label: Antimicrobial treatment
  - id: MAXO:0000174
    label: Antifungal treatment
  - id: HP:0001876
    label: Pancytopenia
  - id: HP:0001945
    label: Fever
  - id: CHEBI:133748
    label: Citrate
  - id: CHEBI:41879
    label: Dexamethasone
  - id: CHEBI:33281
    label: Antimicrobial
  - id: CHEBI:35718
    label: Antifungal
  - id: MONDO:0044033
    label: Posterior reversible encephalopathy syndrome (PRES)
  - id: MAXO:0010030
    label: Bone marrow transplantation
  - id: MAXO:0001188
    label: Laparoscopy
  - id: HP:0000988
    label: Skin rash
  - id: MONDO:0010161
    label: Tyrosinemia Type 1
  - id: HP:0001919
    label: acute kidney injury (AKI)
  - id: HP:0000822
    label: hypertension
  - id: MAXO:0001298
    label: therapy
  - id: HP:0040012
    label: Increased chromosomal breakage
  - id: MONDO:0004631
    label: Tongue cancer (TC)
  - id: CHEBI:4735
    label: EDTA
  - id: HP:0002014
    label: Diarrhea
  - id: HP:0025085
    label: Blood in stool
  - id: HP:0000568
    label: Microphthalmia
  - id: HP:0000482
    label: microcornea
  - id: HP:0000508
    label: ptosis
  - id: HP:0011496
    label: limbal neovascularization
  - id: HP:0001097
    label: keratoconjunctivitis sicca
  - id: CHEBI:62932
    label: Mycophenolate
  - id: MONDO:0008903
    label: Lung Cancer
  - id: MONDO:0100096
    label: COVID-19
  - id: HP:0032169
    label: severe infections
  - id: MONDO:0044348
    label: Hemoglobinopathies
  - id: MONDO:0005109
    label: HIV
  - id: HP:0001622
    label: Preterm delivery
  - id: HP:0100601
    label: Eclampsia
  - id: MONDO:0043455
    label: Hereditary hematological malignancy (HHM)
  - id: MONDO:0043797
    label: Spinal Cord Injury (SCI)
  - id: CHEBI:27306
    label: Vitamin B6
  - id: HP:0001915
    label: aplastic anemia
  - id: MONDO:0001056
    label: Gastric cancer
  - id: MAXO:0001193
    label: Esophagogastroduodenoscopy
  - id: CHEBI:31941
    label: Oxaliplatin
  - id: HP:0012126
    label: Gastric cancer
